Efficacy and tolerability of asenapine for acute mania in bipolar I disorder: Meta-analyses of randomized-controlled trials

International Clinical Psychopharmacology

Volumn 28, Issue 5, 2013, Pages 219-227

  Vita, Antonio ^a,b   De Peri, Luca ^a   Siracusano, Alberto ^c   Sacchetti, Emilio ^a,b  

^a UNIVERSITY OF BRESCIA   (Italy)

^b SPEDALI CIVILI   (Italy)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

asenapine; bipolar disorder; efficacy; meta analysis; randomized controlled trials; tolerability

Indexed keywords

ASENAPINE; OLANZAPINE; PLACEBO;

AKATHISIA; BIPOLAR I DISORDER; BIPOLAR MANIA; BRADYKINESIA; CLINICAL GLOBAL IMPRESSION SCALE; CONSTIPATION; DIZZINESS; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSKINESIA; DYSTONIA; EFFECT SIZE; EXTRAPYRAMIDAL SYMPTOM; GAIT DISORDER; GLUCOSE BLOOD LEVEL; HEADACHE; HUMAN; INSOMNIA; MEDICATION COMPLIANCE; META ANALYSIS; MONOTHERAPY; MONTGOMERY ASBERG DEPRESSION RATING SCALE; NAUSEA; OUTCOME ASSESSMENT; PARKINSONISM; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REFERENCE DATABASE; REVIEW; SEDATION; SIDE EFFECT; SOMNOLENCE; SYSTEMATIC REVIEW; TARDIVE DYSKINESIA; WEIGHT GAIN; YOUNG MANIA RATING SCALE;

ACUTE DISEASE; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; EVIDENCE-BASED MEDICINE; HETEROCYCLIC COMPOUNDS WITH 4 OR MORE RINGS; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84881545081     PISSN: 02681315     EISSN: 14735857     Source Type: Journal    
DOI: 10.1097/YIC.0b013e32836290d2     Document Type: Review

References (30)

1. American Psychiatric Association (2000). Diagnostic and statistical manual of mental disorders. 4th ed. Text revision Arlington, VA: American Psychiatric Association
2. Baruch Y, Tadger S, Plopski I, Barak Y (2013). Asenapine for elderly bipolar manic patients. J Affect Disord 145:130-132
3. Chwieduk CM, Scott LJ (2011). Asenapine: A review of its use in the management of mania in adults with bipolar I disorder. CNS Drugs 25:251-267
4. Cipriani A, Barbui C, Salanti G, Rendell J, Brown R, Stockton S (2011). Comparative efficacy and acceptability of antimanic drugs in acute mania: A multiple-Treatments meta-Analysis. Lancet 378:1306-1315
5. De Hert M, Yu W, Detraux J, Sweers K, van Winkel R, Correll CU (2012). Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: A systematic review and exploratory meta-Analysis. CNS Drugs 26:733-759
6. Egger M, Davey Smith G, Schneider M, Minder C (1997). Bias in meta-Analysis detected by a simple, graphical test. BMJ 315:629-634
7. European Medicines Agency (2010). Summary of product characteristics. Available at: Http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/ medicines/001177/human-med-001379.jsp&mid=WC0b01ac 058001d124. [Accessed 7 May 2013].
8. Gonzalez JM, Thompson PM, Moore TA (2011). Review of the safety, efficacy, and side effect profile of asenapine in the treatment of bipolar 1 disorder. Patient Prefer Adherence 5:333-341
9. Grunze H, Kasper S, Goodwin G, Bowden C, Moller HJ (2004). The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders, part III: Maintenance treatment. World J Biol Psychiatry 5:120-135
10. Hedges LV, Holkin I (1985). Statistical methods for meta-Analysis. New York: Academic Press
11. Hirschfeld RMA (2005). Guideline watch: Practice guideline for the treatment of patients with bipolar disorder. 2nd ed. Arlington, VA: American Psychiatric Association
12. Hirschfeld RM, Keck PE Jr, Kramer M, Karcher K, Canuso C, Eerdekens M, et al. (2004). Rapid antimanic effect of risperidone monotherapy: A 3-week multicenter, double-blind, placebo-controlled trial. Am J Psychiatry 161:1057-1065
13. Keck PE Jr, Marcus R, Tourkodimitris S, Ali M, Liebeskind A, Saha A, et al. (2003a). A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Am J Psychiatry 160:1651-1658
14. Keck PE Jr, Versiani M, Potkin S, West SA, Giller E, Ice K, et al. (2003b). Ziprasidone in the treatment of acute bipolar mania: A three-week, placebo controlled, double-blind, randomized trial. Am J Psychiatry 160:741-748
15. Lew KH, Chang EY, Rajagopalan K, Knoth RL (2006). The effect of medication adherence on health care utilization in bipolar disorder. Manag Care Interface 19:41-46
16. Liauw SS, McIntyre RS (2010). Atypical antipsychotic tolerability and switching strategies in bipolar disorder. Expert Opin Pharmacother 11:2827-2837
17. McIntyre RS, Muzina DJ, Kemp DE, Blank D,Woldeyohannes HO, Lofchy J, et al. (2008). Bipolar disorder and suicide: Research synthesis and clinical translation. Curr Psychiatry Rep 10:66-72
18. McIntyre RS, Cohen M, Zhao J, Alphs L, Macek TA, Panagides J (2009a). A 3-week, randomized, placebo-controlled trial of asenapine in the treatment of acute mania in bipolar mania and mixed states. Bipolar Disord 11:673-686
19. McIntyre RS, Cohen M, Zhao J, Alphs L, Macek TA, Panagides J (2009b). Asenapine versus olanzapine in acute mania: A double-blind extension study. Bipolar Disord 11:815-826
20. McIntyre RS, Cohen M, Zhao J, Alphs L, Macek TA, Panagides J (2010a). Asenapine in the treatment of acute mania in bipolar I disorder: A randomized, double-blind, placebo-controlled trial. J Affect Disord 122:27-38
21. McIntyre RS, Cohen M, Zhao J, Alphs L, Macek TA, Panagides J (2010b). Asenapine for long-Term treatment of bipolar disorder: A double-blind 40-week extension study. J Affect Disord 126:358-365
22. Merck & Co (2012). Saphris (asenapine) sublingual tablets: US prescribing information. Available at: Http://www.spfiles.com/pisaphrisv1.pdf [Accessed 13 November 2012].
23. Potkin SG (2011). Asenapine: A clinical overview. J Clin Psychiatry 72 (Suppl 1): 14-18
24. Stoner SC, Pace HA (2012). Asenapine: A clinical review of a second-generation antipsychotic. Clin Ther 34:1023-1040
25. Suppes T, McElroy SL, Hirschfeld R (2007). Awareness of metabolic concerns and perceived impact of pharmacotherapy in patients with bipolar disorder: A survey of 500 US psychiatrists. Psychopharmacol Bull 40:22-37
26. Szegedi A, Zhao J, van Willigenburg A, Nations KR, Mackle M, Panagides J (2011). Effects of asenapine on depressive symptoms in patients with bipolar I disorder experiencing acute manic or mixed episodes: A post hoc analysis of two 3-week clinical trials. BMC Psychiatry 11:101
27. Szegedi A, Calabrese JR, Stet L, Mackle M, Zhao J, Panagides J. Apollo Study Group (2012). Asenapine as adjunctive treatment for acute mania associated with bipolar disorder: Results of a 12-week core study and 40-week extension. J Clin Psychopharmacol 32:46-55
28. Tohen M, Sanger TM, McElroy SL, Tollefson GD, Chengappa KN, Daniel DG, et al. (1999). Olanzapine versus placebo in the treatment of acute mania. Olanzapine HGEH Study Group. Am J Psychiatry 156:702-709
29. Tohen M, Jacobs TG, Grundy SL, McElroy SL, Banov MC, Janicak PG, et al. (2000). Efficacy of olanzapine in acute bipolar mania: A double-blind, placebo-controlled study. The Olanzapine HGGW Study Group. Arch Gen Psychiatry 57:841-849
30. Yildiz A, Vieta E, Leucht S, Baldessarini RJ (2011). Efficacy of antimanic treatments: Meta-Analysis of randomized, controlled trials. Neuropsychopharmacology 36:375-389